Monday, April 1, 2013
For the second year in a row,
biotech put together a strong showing in the first quarter with all market
segments gaining ground. The sector was led by mid-caps, which closed up 16%.
Large caps were close behind with a 15% gain, marking three
straight quarters in the black. Celgene
Corp. was up 48% for the quarter, the strongest showing in the $5